Bio platform company Altheagen announced that it will participate in 'BIO-Europe 2026,' a global pharmaceutical and biotech partnering event to be held in Cologne, Germany, from the 9th to the 11th.
At this event, Altheagen will conduct business development discussions regarding its candidate drug for macular degeneration, 'ALTS-OP01,' together with its subsidiary Altheagen Biologics. Additionally, the company plans to seek new partnership opportunities for its subcutaneous injection (SC) conversion platform, 'HYBErozyme,' and hold meetings aimed at discovering new pipelines that will serve as medium- to long-term growth drivers.
In particular, ALTS-OP01 is known to have received multiple meeting requests even before the event began. ALTS-OP01 is a multi-target fusion protein candidate drug targeting retinal diseases such as macular degeneration. It is being developed with a mechanism that simultaneously regulates four targets involved in controlling abnormal neovascularization in the cornea and stabilizing blood vessels.
An Altheagen official stated, "CEO Jeon Tae-yeon, who has extensive experience in licensing agreements, plans to directly participate in related meetings so that discussions can lead to specific collaborations." The official added, "We plan to continuously review business opportunities that can broaden our connections with global companies and contribute to medium- to long-term growth through technology adoption and joint development."
Discussions aimed at expanding partnerships for the HYBErozyme platform will also proceed in parallel. Based on research results regarding the conversion of ALT-B4-based ADC (antibody-drug conjugate) formulations to subcutaneous injection, which were presented at the European Society for Medical Oncology annual academic conference 'ESMO 2026,' Altheagen plans to introduce the potential to apply the platform to various treatments and discuss collaboration strategies.
Altheagen is also securing production capacity in parallel with discovering next-generation growth drivers and responding to business expansion. Previously, in August, the company decided on an investment of 253.2 billion won to establish a new biopharmaceutical production facility in the Dungok area of Daejeon.
CEO Jeon stated, "Through global partnering events, we will broaden our connections with various companies and continue business development discussions." He added, "We will do our best to communicate the potential of ALTS-OP01 and the expansion possibilities of the HYBErozyme platform, and to discover pipelines and collaboration opportunities that will become new growth drivers for the company."
in THEBIO
